Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma

Journal of Investigative Dermatology

Volumn 130, Issue 1, 2010, Pages 221-229

  Goto, Yasufumi ^a   Koyanagi, Kazuo ^a   Narita, Norihiko ^a   Kawakami, Yutaka ^b   Takata, Minoru ^c   Uchiyama, Aya ^c   Nguyen, Linhda ^a   Nguyen, Tung ^a   Ye, Xing ^a   Morton, Donald L ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 7; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID BINDING PROTEIN 7 GENE; FEMALE; GENE EXPRESSION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METASTASIS; MICROSATELLITE MARKER; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR GENE;

CARRIER PROTEINS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 6; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; MELANOMA; MICROSATELLITE REPEATS; MULTIVARIATE ANALYSIS; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 72049127502     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.195     Document Type: Article

References (30)

1. Anthony TE, Mason HA, Gridley T, Fishell G, Heintz N (2005) Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. Genes Dev 19:1028-1033
2. Arai Y, Funatsu N, Numayama-Tsuruta K, Nomura T, Nakamura S, Osumi N (2005) Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci 25:9752-9761
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
4. de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ et al. (2005) Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer 92:2249-2261
5. Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T et al. (2007) Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 98:77-82
6. Feng L, Hatten ME, Heintz N (1994) Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. Neuron 12:895-908
7. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL et al. (2004) Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64:2245-2250
8. Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R et al. (1999) Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 59:1567-1571
9. Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K et al. (2006) A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 66:4443-4449
10. Haunerland NH, Spener F (2004) Fatty acid-binding proteins-insights from genetic manipulations. Prog Lipid Res 43:328-349
11. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X et al. (2006) The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer 118:2269-2275
12. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT et al. (2005a) Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23:8057-8064
13. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr et al. (2005b) Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 51:981-988
14. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT et al. (2006) Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 12:1137-1143
15. Kurtz A, Zimmer A, Schnutgen F, Bruning G, Spener F, Muller T (1994) The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development 120:2637-2649
16. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102:5814-5819
17. Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J (1991) Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 51:5449-5453
18. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR (2006) The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 12:4605-4613
19. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N et al. (2005) Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65:1800-1807
20. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317
21. Shi YE, Ni J, Xiao G, Liu YE, Fuchs A, Yu G et al. (1997) Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res 57:3084-3091
22. Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10:1753-1757
23. Shirasaki F, Takata M, Hatta N, Takehara K (2001) Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res 61:7422-7425
24. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63:1639-1643
25. Stark M, Hayward N (2007) Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 67:2632-2642
26. Sweetser DA, Heuckeroth RO, Gordon JI (1987) The metabolic significance of mammalian fatty-acid-binding proteins: abundant proteins in search of a function. Annu Rev Nutr 7:337-359
27. Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R et al. (2004) Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 96:152-156
28. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R et al. (2004) Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22:2671-2680
29. Wong KK, Tsang YT, Chang YM, Su J, Di Francesco AM, Meco D et al. (2006) Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 66:11172-11178
30. Wooten EC, Fults D, Duggirala R, Williams K, Kyritsis AP, Bondy ML et al. (1999) A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro Oncol 1:169-176